
Dalcetrapib
CAS No. 211513-37-0
Dalcetrapib ( JTT-705 | JTT705 | JTT 705 | RO-4607381 )
产品货号. M17429 CAS No. 211513-37-0
Dalcetrapib 是一种 rhCETP 抑制剂 (IC50=0.2 μM),可增加血浆 HDL 胆固醇。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥300 | 有现货 |
![]() ![]() |
5MG | ¥462 | 有现货 |
![]() ![]() |
10MG | ¥583 | 有现货 |
![]() ![]() |
25MG | ¥1094 | 有现货 |
![]() ![]() |
50MG | ¥1709 | 有现货 |
![]() ![]() |
100MG | ¥2989 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Dalcetrapib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Dalcetrapib 是一种 rhCETP 抑制剂 (IC50=0.2 μM),可增加血浆 HDL 胆固醇。
-
产品描述Dalcetrapib, aslo known as JTT-705, is a CETP inhibitor. The drug was aimed at raising the blood levels of "good cholesterol" (cholesterol carried in HDL particles, aka HDL-C). Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health. Development of this drug was halted on May 7, 2012 “due to a lack of clinically meaningful efficacy.(In Vitro):Dalcetrapib (JTT-705) (0.1-10 μM; 21 h) dose-dependently increases pre-β-HDL formation.Dalcetrapib (0-30 μM; 24 h) inhibits the CETP activity of media in HepG2 in a dose-dependent manner.(In Vivo):Dalcetrapib (JTT-705) (30 or 100 mg/kg; p.o.; once a day for 3 days) increases plasma HDL cholesterol in rabbits.Dalcetrapib (100 mg/kg; i.g.; twice daily for 7 days) significantly increases fecal elimination of neutral sterols, bile acids, and plasma HDL-cholesterol.
-
体外实验Dalcetrapib (JTT-705) (0.1-10 μM; 21 h) dose-dependently increases pre-β-HDL formation.Dalcetrapib (0-30 μM; 24 h) inhibits the CETP activity of media in HepG2 in a dose-dependent manner.
-
体内实验Dalcetrapib (JTT-705) (30 or 100 mg/kg; p.o.; once a day for 3 days) increases plasma HDL cholesterol in rabbits.Dalcetrapib (100 mg/kg; i.g.; twice daily for 7 days) significantly increases fecal elimination of neutral sterols, bile acids, and plasma HDL-cholesterol. Animal Model:Male JW rabbits Dosage:30 or 100 mg/kg Administration:Oral administration, once a day for 3 days Result:Increased plasma HDL cholesterol by 27% and 54% at 30 mg/kg and 100 mg/kg, respectively.
-
同义词JTT-705 | JTT705 | JTT 705 | RO-4607381
-
通路Angiogenesis
-
靶点FGFR
-
受体rhCETP
-
研究领域Cardiovascular Disease|Metabolic Disease
-
适应症——
化学信息
-
CAS Number211513-37-0
-
分子量389.59
-
分子式C23H35NO2S
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 50 mg/mL. 128.34 mM; H2O : < 0.1 mg/mL
-
SMILESc1(ccccc1NC(=O)C1(CC(CC)CC)CCCCC1)SC(=O)C(C)C
-
化学全称S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Niesor EJ, et al. J Lipid Res. 2010, 51(12), 3443-3454.